Conjupro Biotherapeutics, Inc.
Subsidiary of CSPC Pharmaceutical Group (1093)
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | EGFRAntibody–drug conjugate | Non-Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaBreast Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.